1. A method of forming an integrated circuit, the method comprising:
providing a semiconductor substrate;
forming a low-k dielectric layer over the semiconductor substrate;
forming an opening extending from a top surface of the low-k dielectric layer into the low-k dielectric layer;
forming a diffusion barrier layer in the opening covering the low-k dielectric layer in the opening, wherein the diffusion barrier layer has a top edge substantially level with a top surface of the low-k dielectric layer;
filling a copper line into the opening;
recessing a top surface of the copper line; and
forming a metal cap on the copper line using a selective deposition method, wherein the metal cap is only formed substantially within a region directly over the copper line.
2. The method of claim 1, wherein the metal cap has a top surface higher or lower than the top edge of the diffusion barrier layer.
3. The method of claim 2, wherein the step of recessing the top surface of the copper line comprises:
oxidizing the top surface of the copper line to form a copper oxide layer; and
removing the copper oxide layer from the top surface of the copper line.
4. The method of claim 3, wherein the step of oxidizing the top surface of the copper line comprises oxygen plasma oxidation.
5. The method of claim 1 further comprising reducing a copper oxide layer on the top surface of the copper line to copper.
6. The method of claim 1, wherein the step of forming the metal cap is performed using electroless plating.
7. The method of claim 6, wherein the electroless plating is free from palladium catalysts.
8. The method of claim 1, wherein the diffusion barrier has a spacing from an additional diffusion barrier layer of a neighboring copper line, and wherein a ratio of the spacing to a combined width of the copper line and the diffusion barrier layer is less than about one.
9. A method of forming an integrated circuit, the method comprising:
providing a semiconductor substrate;
forming a low-k dielectric layer over the semiconductor substrate;
forming a opening extending from a top surface of the low-k dielectric layer into the low-k dielectric layer;
forming a diffusion barrier layer in the opening and covering the low-k dielectric layer in the opening;
filling copper into the opening;
planarizing the copper to form a copper line;
oxidizing a top layer of the copper line to form a copper oxide layer;
removing the copper oxide layer; and
forming a metal cap on the copper line.
10. The method of claim 9 further comprising forming a chemical mechanical polish (CMP) stop layer on the low-k dielectric layer before the step of forming the opening, wherein after the step of planarizing the copper, a top edge of the diffusion barrier layer is level with a top surface of the CMP stop layer.
11. The method of claim 9, wherein the metal cap is formed using electroless plating with palladium-free catalysts, and wherein the metal cap is only within a region directly over the copper line.
12. The method of claim 9 wherein after the step of planarizing the copper, horizontal portions of the diffusion barrier layer are removed.
13. The method of claim 9, wherein the step of oxidizing the top layer of the copper line comprises oxygen plasma oxidation.
14. The method of claim 9 further comprising, before the step of forming the metal layer, reducing a copper oxide layer on a top surface of the copper line to copper.
15. The method of claim 14, wherein the step of reducing is performed in a reduction solution comprising a cyclic borane compound selected from the group consisting essentially of morpholine borane, piperidine borane, pyridine borane, piperazine borane, 2,6-lutidine borane, N,N-diethylaniline borane, 4-methylmorpholine borane, and 1,4-oxathiane borane, and combinations thereof, and wherein the reduction solution further comprises a reducer selected from the group consisting essentially of dimethylaminoborane (DMAB), diethylaminoborane, morpholine borane, and combinations thereof.
16. The method of claim 14, wherein the step of reducing is performed in a reduction solution comprising a reducer selected from the group consisting essentially of ammonium, alkali, alkaline earth metal borohydrides, hypophosphites, sulfites, bisulfites, hydrosulfites, metabisulfites, dithionates, tetrathionates, thiosulfates, thioureas, hydrazines, hydroxylamines, aldehydes (including formaldehyde and glyoxal), glyoxylic acid, reducing sugars, and combinations thereof.
17. The method of claim 14, wherein the step of reducing is performed by applying a current in an alkaline-based solution.
18. The method of claim 9, wherein the metal cap has a top surface higher or lower than the top edge of the diffusion barrier layer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula I:
wherein:
A or B is N and the other is CH;
Y and Z are independently hydroxy, (C1-C6)alkoxy, substituted (C1-C6)alkoxy, (C1-C6)alkanoyloxy, substituted (C1-C6) alkanoyloxy, \u2014O\u2014P(\u2550O)(OH)2, or \u2014O\u2014C(\u2550O)NRcRd; or Y and Z together with the ring carbon atoms to which they are attached form an alkylenedioxy ring with from 5 to 7 ring atoms;
R1 is (C1-C6)alkyl; and
Rc and Rd are each independently (C1-C6) alkyl or substituted (C1-C6) alkyl; or Rc and Rd together with the nitrogen to which they are attached form a N\u2032\u2014(C1-C6)alkylpiperazino, pyrrolidino, or piperidino ring, which ring can optionally be substituted with one or more aryl, heteroaryl, or heterocycle;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein A is N.
3. The compound of claim 1 wherein A is CH.
4. The compound of claim 1 wherein Y is OH.
5. The compound of claim 1 wherein Y is (C1-C6)alkoxy.
6. The compound of claim 1 wherein Y is \u2014OCH3.
7. The compound of claim 1 wherein Y is substituted (C1-C6)alkoxy.
8. The compound of claim 1 wherein Y is \u2014OCH2CH2OH.
9. The compound of claim 1 wherein Y is \u2014OCH2CH2OCH2CH3.
10. The compound of claim 1 wherein Y is \u2014O\u2014CH2\u2014CHOH\u2014CH2\u2014OH.
11. The compound of claim 1 wherein Y is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb are hydrogen or (C1-C6)alkyl.
12. The compound of claim 1 wherein Y is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb together with the nitrogen to which they are attached form a piperazino, pyrrolidino, piperidino, morpholino, or thiomorpholino ring.
13. The compound of claim 1 wherein Y is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
14. The compound of claim 1 wherein Y is \u2014O\u2014C(\u2550O)\u2014CHOH\u2014CH2\u2014OH.
15. The compound of claim 1 wherein Y is (C1-C6)alkyl substituted with one or more tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl rings.
16. The compound of claim 1 wherein Y is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
17. The compound of claim 1 wherein Z is OH.
18. The compound of claim 1 wherein Z is (C1-C6)alkoxy.
19. The compound of claim 1 wherein Z is OCH3.
20. The compound of claim 1 wherein Z is substituted (C1-C6)alkoxy.
21. The compound of claim 1 wherein Z is \u2014OCH2CH2OH.
22. The compound of claim 1 wherein Z is \u2014OCH2CH2OCH2CH3.
23. The compound of claim 1 wherein Z is \u2014O\u2014CH2\u2014CHOH\u2014CH2\u2014OH.
24. The compound of claim 1 wherein Z is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb are hydrogen or (C1-C6)alkyl.
25. The compound of claims 1 wherein Z is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb together with the nitrogen to which they are attached form a piperazino, pyrrolidino, piperidino, morpholino, or thiomorpholino ring.
26. The compound of claim 1 wherein Z is \u2014O\u2014C(\u2550O)\u2014CHOH\u2014CH2\u2014OH.
27. The compound of claim 1 wherein Z is (C1-C6)alkyl substituted with one or more tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl rings.
28. The compound of claim 1 wherein Z is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
29. The compound of claim 1 wherein R1 is (C1-C6)alkyl.
30. The compound of claim 1 wherein R1 is methyl.
31. The compound of claim 1 wherein R1 is ethyl.
32. The compound of claim 1 wherein R1 is propyl.
33. The compound of claim 1 wherein R1 is isopropyl.
34. The compound of claim 1 wherein R1 is n-butyl.
35. The compound of claim 1 wherein R1 is iso-butyl.
36. The compound of claim 1 wherein R1 is n-pentyl.
37. The compound of claim 1 wherein R1 is isopentyl.
38. The compound of claim 1 wherein R1 is n-hexyl.
39. The compound 12-ethyl-2,3-dimethoxy-12H-8,10-dioxa-6,12-diaza-cyclopentabchrysen-13-one and 12-butyl-2,3-dimethoxy-12H-8,10-dioxa-6,12-diaza-cyclopentabchrysen-13-one, or a pharmaceutically acceptable salt thereof.
40. A compound of formula II:
wherein:
A or B is N and the other is CH;
W is CH;
R3 and R4 are both H, or R3 and R4 together are \u2550O, \u2550S, \u2550NH or \u2550N\u2014R2 wherein R2 is (C1-C6)alkyl or substituted (C1-C6)alkyl;
Y and Z are independently hydroxy, (C1-C6)alkoxy, substituted (C1-C6)alkoxy, (C1-C6)alkanoyloxy, substituted (C1-C6) alkanoyloxy, \u2014O\u2014P(\u2550O)(OH)2, or \u2014O\u2014C(\u2550O)NRcRd; or Y and Z together with the ring carbon atoms to which they are attached form an alkylenedioxy ring with from 5 to 7 ring atoms;
R1 is hydrogen or (C1-C6)alkyl; and
Rc and Rd are each independently (C1-C6) alkyl or substituted (C1-C6) alkyl; or Rc and Rd together with the nitrogen to which they are attached form a N\u2032\u2014(C1-C6)alkylpiperazino, pyrrolidino, or piperidino ring, which ring can optionally be substituted with one or more aryl, heteroaryl, or heterocycle;
provided that at least one or both A and B is N; and
provided that when R3 and R4 are both H then W is CH;
or a pharmaceutically acceptable salt thereof.
41. The compound of claim 40 wherein A is N.
42. The compound of claim 40 wherein A is CH.
43. The compound of claim 40 wherein Y is OH.
44. The compound of claim 40 wherein Y is (C1-C6)alkoxy.
45. The compound of claim 40 wherein Y is \u2014OCH3.
46. The compound of claim 40 wherein Y is substituted (C1-C6)alkoxy.
47. The compound of claim 40 wherein Y is \u2014OCH2CH2OH.
48. The compound of claim 40 wherein Y is \u2014OCH2CH2OCH2CH3.
49. The compound of claim 40 wherein Y is \u2014O\u2014CH2\u2014CHOH\u2014CH2\u2014OH.
50. The compound of claim 40 wherein Y is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb are hydrogen or (C1-C6)alkyl.
51. The compound of claim 40 wherein Y is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb together with the nitrogen to which they are attached form a piperazino, pyrrolidino, piperidino, morpholino, or thiomorpholino ring.
52. The compound of claim 40 wherein Y is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
53. The compound of claim 40 wherein Y is \u2014O\u2014C(\u2550O)\u2014CHOH\u2014CH2\u2014OH.
54. The compound of claim 40 wherein Y is (C1-C6)alkyl substituted with one or more tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl rings.
55. The compound of claim 40 wherein Y is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
56. The compound of claim 40 wherein Z is OH.
57. The compound of claim 40 wherein Z is (C1-C6)alkoxy.
58. The compound of claim 40 wherein Z is OCH3.
59. The compound of claim 40 wherein Z is substituted (C1-C6)alkoxy.
60. The compound of claim 40 wherein Z is \u2014OCH2CH2OH.
61. The compound of claim 40 wherein Z is \u2014OCH2CH2OCH2CH3.
62. The compound of claim 40 wherein Z is \u2014O\u2014CH2\u2014CHOH\u2014CH2\u2014OH.
63. The compound of claim 40 wherein Z is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb are hydrogen or (C1-C6)alkyl.
64. The compound of claim 40 wherein Z is \u2014O\u2014CH2CH2\u2014NRaRb wherein Ra and Rb together with the nitrogen to which they are attached form a piperazino, pyrrolidino, piperidino, morpholino, or thiomorpholino ring.
65. The compound of claim 40 wherein Z is \u2014O\u2014C(\u2550O)\u2014CHOH\u2014CH2\u2014OH.
66. The compound of claim 40 wherein Z is (C1-C6)alkyl substituted with one or more tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl rings.
67. The compound of claim 40 wherein Z is \u2014O\u2014C(\u2550O)CH2\u2014NRaRb.
68. The compound of claim 40 wherein R3 and R4 are both H.
69. The compound of claim 40 wherein R3 and R4 together are \u2550O.
70. The compound of claim 40 wherein R3 and R4 together are \u2550S.
71. The compound of claim 40 wherein R3 and R4 together are \u2550NH.
72. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 is (C1-C6)alkyl.
73. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 is substituted (C1-C6)alkyl.
74. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 is a (C1-C6)alkyl substituted with one or more hydroxy, mercapto, carboxy, amino, piperazinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl groups.
75. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 has from 2 to 4 carbon atoms and substituted with one to two groups selected from hydroxy, mercapto, carboxy, amino, piperazinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, or 1,4-dioxanyl.
76. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 is \u2014CH2CH2\u2014NRaRb wherein Ra and Rb are hydrogen or (C1-C6)alkyl.
77. The compound of claim 40 wherein R3 and R4 together are \u2550N\u2014R2 where R2 is \u2014CH2C H2-NRaRb wherein Ra and Rb together with the nitrogen to which they are attached form a piperazino, pyrrolidino, piperidino, morpholino, or thiomorpholino ring.
78. The compound of claim 40 wherein R1 is hydrogen.
79. The compound of claim 40 wherein R1 is (C1-C6)alkyl.
80. The compound of claim 40 wherein R1 is isobutyl.
81. The compound of claim 40 wherein R1 is n-butyl.
82. The compound of claim 40 wherein R1 is isopentyl.
83. The compound 12-butyl-2,3-dimethoxy-12H-8,10-dioxa-4,5,6,12-tetraaza-cyclopentabchrysen-13-one; 12-butyl-2,3-dimethoxy-12H-8,10-dioxa-1,5,6,12-tetraaza-cyclopentabchrysen-13-one; 12-butyl-2,3-dimethoxy-12H-8,10-dioxa-1,4,5,6,12-pentaaza-cyclopentabchrysen-13-one; or a pharmaceutically acceptable salt thereof.
84. A pharmaceutical composition comprising a compound as described in claim 1, or 40 in combination with a pharmaceutically acceptable diluent or carrier.
85. A method of inhibiting breast cancer cell growth, comprising administering to a mammal afflicted breast with cancer, an amount of a compound as described in claim 1, or 40 effective to inhibit the growth of said breast cancer cells.
86. A method comprising inhibiting breast cancer cell growth by contacting said breast cancer cell in vitro or in vivo with an amount of a compound as described in claim 1, or 40 effective to inhibit the growth of said breast cancer cell.